Equities analysts expect Pieris Pharmaceuticals Inc (NASDAQ:PIRS) to post earnings per share of ($0.14) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Pieris Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.12) and the lowest estimate coming in at ($0.15). Pieris Pharmaceuticals posted earnings of ($0.16) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 12.5%. The firm is expected to report its next quarterly earnings results on Wednesday, March 28th.
According to Zacks, analysts expect that Pieris Pharmaceuticals will report full year earnings of ($0.72) per share for the current fiscal year, with EPS estimates ranging from ($0.73) to ($0.70). For the next year, analysts expect that the company will report earnings of ($0.63) per share, with EPS estimates ranging from ($0.74) to ($0.51). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Pieris Pharmaceuticals.
Pieris Pharmaceuticals (NASDAQ:PIRS) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. Pieris Pharmaceuticals had a negative net margin of 321.83% and a negative return on equity of 221.93%. The firm had revenue of $3.93 million during the quarter, compared to analysts’ expectations of $1.52 million. The firm’s revenue was up 400.3% on a year-over-year basis.
Pieris Pharmaceuticals (NASDAQ PIRS) opened at $7.46 on Monday. The firm has a market cap of $334.17, a PE ratio of -10.22 and a beta of -76.25. Pieris Pharmaceuticals has a 12 month low of $1.66 and a 12 month high of $7.90.
In related news, major shareholder Orbimed Advisors Llc sold 147,635 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $5.70, for a total value of $841,519.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.05% of the stock is owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the business. Teachers Advisors LLC acquired a new stake in Pieris Pharmaceuticals during the second quarter worth approximately $308,000. First Quadrant L P CA acquired a new stake in Pieris Pharmaceuticals during the third quarter worth approximately $473,000. Northern Trust Corp acquired a new position in shares of Pieris Pharmaceuticals in the 2nd quarter valued at $1,625,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Pieris Pharmaceuticals in the 2nd quarter valued at $292,000. Finally, Voya Investment Management LLC acquired a new position in shares of Pieris Pharmaceuticals in the 2nd quarter valued at $100,000. 50.45% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Week Herald and is owned by of Week Herald. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://weekherald.com/2018/01/15/analysts-anticipate-pieris-pharmaceuticals-inc-pirs-to-announce-0-14-eps.html.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.